CONMED (CNMD)
(Delayed Data from NYSE)
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 5:18 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 5:18 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Earnings Preview: Conmed (CNMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain CONMED (CNMD) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Conmed (CNMD) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HSIC vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
HSIC vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
CONMED's (CNMD) Q2 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
CONMED (CNMD) witnesses revenue uptick in both of its segments during Q2 despite continued pandemic-led business disruptions.
Conmed (CNMD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 14.52% and 2.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
LH vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Align Technology (ALGN) Launches New Features in iTero Family
by Zacks Equity Research
Align Technology's (ALGN) iTero Workflow 2.0 software and iTero Element 5D Imaging system auto-upload functionality to drive innovation in digital orthodontics and restorative dentistry.
Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Henry Schein (HSIC) Clinches HHS Deal for COVID-19 Supplies
by Zacks Equity Research
Henry Schein (HSIC) to extend effective inventory management and extensive logistical support for PPE and COVID related products within the spectrum of U.S. health care.
Medtronic (MDT) Diabetes Arm Secures Two Approvals in Europe
by Zacks Equity Research
These two latest innovations are likely to enable Medtronic (MDT) to offer the only pump that adjusts and corrects every five minutes with an infusion set that lasts twice as long.
Why Is Conmed (CNMD) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HSIC vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.
Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.
CONMED (CNMD) Surges 4.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
CONMED (CNMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.